Tacalyx
VerifiedTacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$31—46m (Dealroom.co estimates Sep 2019.)
Company register number HRB 32607 P (Potsdam)
Berlin Germany (HQ)
Authorizing premium user...